107.png(1).png

CLINICAL TRIAL PARTICIPANTS.


107 DMD patients received at least one intravenous dose of EXONDYS 51, ranging from between 0.5 mg/kg (0.017 times the recommended dose) and 50 mg/kg (1.7 times the recommended dose). All patients were male and had genetically confirmed DMD. Age at study entry was 4 to 19 years. Most (89%) patients were Caucasian.1

STUDY 11

PARTICIPANTS  N=12
Trial type double-blind, placebo-controlled
Trial length 24 weeks
Received weekly infusions of EXONDYS 51 n=8
Received placebo n=4

4 patients received placebo, 4 patients received EXONDYS 51 30 mg/kg, and 4 patiemts received EXONDYS 51 50 mg/kg (1.7 times the recommended dose). All 12 patients continued in Study 2.

STUDY 21

PARTICIPANTS N=12
Trial type Open label extension of Study 1
Trial length up to 208 weeks
Received weekly infusions of EXONDYS 51 n=12

6 patients received EXONDYS 51 30 mg/kg/week, and 6 patients received EXONDYS 51 50 mg/kg/week.

 


STUDY 1: ADVERSE REACTIONS1

In DMD patients treated with 30 or 50 mg/kg/week EXONDYS 51

with incidence at least 25% more than placebo:

ADVERSE REACTIONS EXONDYS 51 | N=8 (%) PLACEBO | N=4 (%)
Balance disorder 38% 0%
Vomiting 38% 0%
Contact dermatitis 25% 0%

30-mg/kg and 50-mg/kg groups were pooled. 50 mg/kg/week = 1.7 times the recommended dosage.

 

Because of the small numbers of patients, these values represent crude frequencies that may not reflect the frequencies observed in practice.1

 


  • The 50 mg/kg once-weekly dosing regimen of EXONDYS 51 is not recommended.1
  • In the 88 patients who received ≥30 mg/kg/week of EXONDYS 51 for up to 208 weeks in clinical studies, the following events were reported in ≥10% of patients and occurred more frequently than with the same dose in Study 1: vomiting, contusion, excoriation, arthralgia, rash, catheter site pain, and upper respiratory tract infection.1
  • Hypersensitivity reactions, including rash and urticaria, pyrexia, flushing, cough, dyspnea, bronchospasm, and hypotension have occurred in patients who were treated with EXONDYS 51. If a hypersensitivity reaction occurs, institute appropriate medical treatment and consider slowing the infusion or interrupting the EXONDYS 51 therapy.1

 


meetgraysen.jpeg

 

MEET GRAYSEN
DMD PATIENT WITH
DELETIONS OF EXONS 48-50

GET THE LATEST UPDATES FROM SAREPTA.

Sign up for the news from Sarepta Therapeutics, including product updates, reimbursement information, and services that may be of interest to you and your patients.

INDICATION

EXONDYS 51 is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping. This indication is approved under accelerated approval based on an increase in dystrophin in skeletal muscle observed in some patients treated with EXONDYS 51. A clinical benefit of EXONDYS 51 has not been established. Continued approval for this indication may be contingent upon verification of a clinical benefit in confirmatory trials.

Read More

IMPORTANT SAFETY INFORMATION

Hypersensitivity reactions, including rash and urticaria, pyrexia, flushing, cough, dyspnea, bronchospasm, and hypotension, have occurred in patients who were treated with EXONDYS 51. If a hypersensitivity reaction occurs, institute appropriate medical treatment and consider slowing the infusion or interrupting the EXONDYS 51 therapy.

Adverse reactions in DMD patients (N=8) treated with EXONDYS 51 30 or 50 mg/kg/week by intravenous (IV) infusion with an incidence of at least 25% more than placebo (N=4) (Study 1, 24 weeks) were (EXONDYS 51, placebo): balance disorder (38%, 0%), vomiting (38%, 0%) and contact dermatitis (25%, 0%). The most common adverse reactions were balance disorder and vomiting. Because of the small numbers of patients, these represent crude frequencies that may not reflect the frequencies observed in practice. The 50 mg/kg once weekly dosing regimen of EXONDYS 51 is not recommended.

In the 88 patients who received ≥30 mg/kg/week of EXONDYS 51 for up to 208 weeks in clinical studies, the following events were reported in ≥10% of patients and occurred more frequently than on the same dose in Study 1: vomiting, contusion, excoriation, arthralgia, rash, catheter site pain, and upper respiratory tract infection.

Please see the full Prescribing Information for EXONDYS 51 (eteplirsen).

 

 

Reference

  1. EXONDYS 51 [package insert]. Cambridge, MA: Sarepta Therapeutics Inc; October 2018.